Nicotinic acetylcholine receptors containing the α4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption.
Recently, we investigated the molecular mechanisms of the smoking cessation drug varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, in its ability to decrease voluntary ethanol intake in mice. Previous to our study, other labs had shown that this drug can decrease ethanol consumption and seeking in rat models of ethanol intake. Although varenicline was designed to be a high affinity partial agonist of nAChRs containing the α4 and β2 subunits (designated as α4β2*), at higher concentrations it can also act upon α3β2*, α6*, α3β4* and α7 nAChRs. Therefore, to further elucidate the nAChR subtype responsible for varenicline-induced reduction of ethanol consumption, we utilized a pharmacological approach in combination with two complimentary nAChR genetic mouse models, a knock-out line that does not express the α4 subunit (α4 KO) and another line that expresses α4* nAChRs hypersensitive to agonist (the Leu9'Ala line). We found that activation of α4* nAChRs was necessary and sufficient for varenicline-induced reduction of alcohol consumption. Consistent with this result, here we show that a more efficacious nAChR agonist, nicotine, also decreased voluntary ethanol intake, and that α4* nAChRs are critical for this reduction.
Brudnick Neuropsychiatric Research Institute, University of Massachusetts Medical School, Worcester, MA, USA.
Linzy M
LM
Hendrickson
Paul
P
Gardner
Andrew R
AR
Tapper
D000428:Alcohol Drinking; D000818:Animals; D001522:Behavior, Animal; D001552:Benzazepines / Q000494:pharmacology; D000431:Ethanol / Q000494:pharmacology; D005838:Genotype; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008957:Models, Genetic; D009538:Nicotine / Q000378:metabolism*; D018722:Nicotinic Agonists / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000235:genetics / Q000378:metabolism*; D000068580:Varenicline
D001552:Benzazepines; D000431:Ethanol; D009538:Nicotine; D018722:Nicotinic Agonists; D011810:Quinoxalines; D011978:Receptors, Nicotinic; D000068580:Varenicline
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12518-23
17626178
Pharmacopsychiatry. 2009 May;42 Suppl 1:S87-94
19434560
Mol Pharmacol. 2004 Jun;65(6):1526-35
15155845
Physiol Rev. 2009 Jan;89(1):73-120
19126755
Physiol Behav. 2005 Jan 31;84(1):53-63
15642607
Science. 2004 Nov 5;306(5698):1029-32
15528443
Psychopharmacology (Berl). 2009 Jul;204(4):563-72
19247637
J Neurosci. 2000 Sep 1;20(17):6431-41
10964949
Psychopharmacology (Berl). 2010 Mar;208(4):613-26
20072781
Alcohol. 2002 Nov;28(3):157-67
12551757
Biomed Pharmacother. 2004 Mar;58(2):111-5
14992792
Alcohol Res Health. 2000;24(4):225-32
15986717
Nature. 1998 Jan 8;391(6663):173-7
9428762
JAMA. 2006 Jul 5;296(1):56-63
16820547
Mol Pharmacol. 2006 Aug;70(2):755-68
16720757
Biol Psychiatry. 2009 Jul 15;66(2):185-90
19249750
J Med Chem. 2005 May 19;48(10):3474-7
15887955
Eur J Pharmacol. 1998 Oct 9;358(3):189-96
9822883
J Pharmacol Exp Ther. 2009 Apr;329(1):225-30
19126781
Behav Brain Res. 2000 Aug;113(1-2):85-96
10942035
Eur J Pharmacol. 1997 Sep 10;334(2-3):149-56
9369343
J Neurosci. 2010 Jul 28;30(30):10169-76
20668200
Mol Pharmacol. 2006 Sep;70(3):801-5
16766716